A Phase 4 interventional study of Everolimus and Tacrolimus (FK506) in Chronic Renal Failure, sponsored by Novartis Pharmaceuticals. Completed at 3 sites in Israel. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-08-15.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Kidney Failure, Chronic with a site in Israel — 3 open to participants now, 5 under way, 2 of them phase 3. Kidney Failure, Chronic · Israel.
Among the 40 studies in Kidney Failure, Chronic with a site in Israel, this one is the 22nd largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2009, is one of 3 in phase 4, and was the 14th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →3 of the 40 studies in Kidney Failure, Chronic with a site in Israel are open now. Recruiting first, the newest first:
CSL Behring · Sites in Israel, United States, Argentina and 32 more countries
Ages 18+
The University of Queensland · Sites in Israel, Australia, Brazil and 6 more countries
Ages 18+
Rigshospitalet, Denmark · Sites in Israel, Argentina, Austria and 33 more countries
Ages 16+
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 9 · Phase 4 3
First in 1994; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 160 across the 29 interventional studies, 210 across the 8 observational. Of the 28 that completed or were terminated, 13 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 40 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 7 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 40 studies in Kidney Failure, Chronic with a site in Israel, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this trial is to show non-inferiority of a CNI-free regimen with respect to the renal function at Month 9 post Tx assessed by glomerular filtration rate - Nankivell method - as compared to the standard CNI-based regimen in de novo renal transplant patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
At BL1, all study patients received induction therapy with basiliximab (Simulect®; 2x20mg on day 0 - 2 hours prior to transplantation, and on day 4 after transplantation) and commenced an immunosuppressive regimen consisting of MPA (Myfortic®; target dose: 1440 mg/day, which was also the maximum daily dose) + tacrolimus (Prograf®; based on C0-h levels; Table 9-2) and with corticosteroids. AT BL2 \[Month 3 (+1 week) after transplantation\], eligible patients were randomized, using living and cadaveric donation as stratum. Patients were switched to the CNI-free regimen. Everolimus was added to the patients immunosuppressive regimen and tacrolimus was removed successively.
Drug: Everolimus · Drug: Basiliximab · Drug: Enteric Coated Mycophenolate Sodium (EC-MPS) · Drug: Corticosteroids
At BL1, all study patients received induction therapy with basiliximab (Simulect®; 2x20mg on day 0 - 2 hours prior to transplantation, and on day 4 after transplantation) and commenced an immunosuppressive regimen consisting of MPA (Myfortic®; target dose: 1440 mg/day, which was also the maximum daily dose) + tacrolimus (Prograf®; based on C0-h levels; Table 9-2) and with corticosteroids. AT BL2 \[Month 3 (+1 week) after transplantation\], eligible patients were randomized, using living and cadaveric donation as stratum. Patients continued on the prior immunosuppressive regimen consisting of MPA + tacrolimus with corticosteroids.
Drug: Tacrolimus (FK506) · Drug: Basiliximab · Drug: Enteric Coated Mycophenolate Sodium (EC-MPS) · Drug: Corticosteroids
One tablet containing 0.25, 0.5mg or 0.75 mg. Initially 2 mg/day. Afterwards based on blood level (target 6-10 ng/mL)
Also known as: Certican
Capsules 0.5 mg, 1 mg. Dosing according to blood level.
Also known as: Prograf
One vial containing 20 mg lyophilisate. 2 x 20 mg \[day 0 (2 hrs prior to Tx) and day 4 post Tx\] to be applied as 10 sec. bolus injection, i.v.
Also known as: Simulect
One tablet containing 180 mg or 360 mg. 1440 mg/day (2x720 mg). If tolerated, dose reduction due to side effectis were possible (min. dose at BL@: 720 mg/day)
Also known as: Myfortic
Used according to Israeli standards. A minimum dose of 5mg \[prednisone, or equivalent, was used throughout the study period.
Renal Function Assessed as Glomerula Filtration Rate (GFR) - Nankivell Method - 9 Months After Renal Transplantation (LOCF)
The glomerular filtration rate (GFR) is the best clinical estimate of renal function in health and disease, and correlates well with the clinical severity of renal function disturbances. The GFR, calculated according to the Nankivell formula, was used as the primary outcome measure in this study. This equation has been validated in renal transplant patients against the true GFR measured by a radionuclide method and has been confirmed as a very accurate method to calculate the GFR in this specific population (Gaspari et al., 2004)GFR = 6.7 / Scr + BW / 4 - Surea / 2-100 / (height)² + C Scr = serum creatinine concentration expressed in mmol/L. BW = body weight in kg, Surea = serum urea in mmol/L and Height is expressed in meters.The Last Observation Carried Forward (LOCF) imputation technique was used for this analysis.
Time frame: 9 months
Assessment of GFR by the Cockcroft-Gault Method (LOCF)
the GFR was also calculated using the Cockcroft-Gault method (Cockcroft and Gault 1976) and the Modification of Diet in Renal Disease (MDRD) method (Levey et al., 1999, Rodrigo et al., 2003; Pierrat et al., 2003).Cockcroft-Gault formula For men: GFR= (140-Age)X Body Weight\[kg\]/72X Serum Creatinine\[mg/dl\] For women: GFR= 0,85x(140-Age) x Body Weight\[kg\]/72x Serum Creatinine \[mg/dl\] The Last Observation Carried Forward (LOCF) imputation technique was used for this analysis.
Time frame: 9 months
Participants Who Had Occurrence of Biopsy Proven Acute Rejection, Graft Loss or Death.
Biopsy-proven acute rejection was defined as a biopsy gradeed IA, IB, IIA, IIB, or III. The allograft was presumed to be lost if the patient started dialysis and was not able to subsequently be removed from dialysis. If the patient underwent a graft nephrectomy, then the day of nephrectomy was the day of graft loss.
Time frame: 9 months
Participants Who Had Occurrence of Treatment Failure.
Treatment failure was defined as a composite endpoint of biopsy-proven acute rejection, graft loss, death, loss to follow up, discontinuation due to lack of efficacy or toxicity or conversion to another regimen.
Time frame: 9 months
Change in Renal Function (Creatinine Slope)
X(slope)=(1/value of creatinine).
Time frame: 3 months, 5 months, 7 months, 9 months
| Milestone | Everolimus | Reference Therapy |
|---|---|---|
| Started | 19 | 17 |
| Completed | 14 | 16 |
| Not completed | 5 | 1 |
| Withdrew: Adverse event | 5 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
The glomerular filtration rate (GFR) is the best clinical estimate of renal function in health and disease, and correlates well with the clinical severity of renal function disturbances. The GFR, calculated according to the Nankivell formula, was used as the primary outcome measure in this study. This equation has been validated in renal transplant patients against the true GFR measured by a radionuclide method and has been confirmed as a very accurate method to calculate the GFR in this specific population (Gaspari et al., 2004)GFR = 6.7 / Scr + BW / 4 - Surea / 2-100 / (height)² + C Scr = serum creatinine concentration expressed in mmol/L. BW = body weight in kg, Surea = serum urea in mmol/L and Height is expressed in meters.The Last Observation Carried Forward (LOCF) imputation technique was used for this analysis.
| mL/min/1.73m^2 | Everolimus | Reference Therapy |
|---|---|---|
| Renal Function Assessed as Glomerula Filtration Rate (GFR) - Nankivell Method - 9 Months After Renal Transplantation (LOCF) | 15.0 ± 10.3 | 16.6 ± 7.0 |
the GFR was also calculated using the Cockcroft-Gault method (Cockcroft and Gault 1976) and the Modification of Diet in Renal Disease (MDRD) method (Levey et al., 1999, Rodrigo et al., 2003; Pierrat et al., 2003).Cockcroft-Gault formula For men: GFR= (140-Age)X Body Weight\[kg\]/72X Serum Creatinine\[mg/dl\] For women: GFR= 0,85x(140-Age) x Body Weight\[kg\]/72x Serum Creatinine \[mg/dl\] The Last Observation Carried Forward (LOCF) imputation technique was used for this analysis.
| mL/min | Everolimus | Reference Therapy |
|---|---|---|
| Assessment of GFR by the Cockcroft-Gault Method (LOCF) | 72.6 ± 18.9 | 72.7 ± 20.5 |
Biopsy-proven acute rejection was defined as a biopsy gradeed IA, IB, IIA, IIB, or III. The allograft was presumed to be lost if the patient started dialysis and was not able to subsequently be removed from dialysis. If the patient underwent a graft nephrectomy, then the day of nephrectomy was the day of graft loss.
| Participants | Everolimus | Reference Therapy |
|---|---|---|
| No | 14 | 14 |
| Yes | 1 | 1 |
Treatment failure was defined as a composite endpoint of biopsy-proven acute rejection, graft loss, death, loss to follow up, discontinuation due to lack of efficacy or toxicity or conversion to another regimen.
| Participants | Everolimus | Reference Therapy |
|---|---|---|
| No | 10 | 14 |
| Yes | 5 | 1 |
X(slope)=(1/value of creatinine).
| mg/dl per month | Everolimus | Reference Therapy |
|---|---|---|
| (ITT) Baseline 2: Month 3 N=15, 15 | 0.7 ± 0.1 | 0.7 ± 0.2 |
| (ITT) Month 3 (1st week) N=15, 4 | 0.7 ± 0.2 | 0.8 ± 0.1 |
| (ITT) Month 3 (2nd week) N=15, 4 | 0.8 ± 0.1 | 0.9 ± 0.2 |
| (ITT) Month 3 (3rd week) N=13, 2 | 0.7 ± 0.1 | 0.9 ± 0.2 |
| (ITT) Month 3 (4th week) N=12, 0* | 0.8 ± 0.1 | NA ± NA |
| (ITT) Month 5 N=14, 15 | 0.8 ± 0.2 | 0.7 ± 0.2 |
| (ITT) Month 7 N=14, 14 | 0.7 ± 0.2 | 0.7 ± 0.2 |
| (ITT) Month 9 N=11, 15 | 0.8 ± 0.2 | 0.8 ± 0.2 |
| (PP) Baseline 2: Month 3 N=11, 15 | 0.7 ± 0.1 | 0.7 ± 0.2 |
| (PP) Month 3 (first week) N=11, 4 | 0.7 ± 0.2 | 0.8 ± 0.1 |
| (PP) Month 3 (second week) N=11, 4 | 0.8 ± 0.1 | 0.9 ± 0.2 |
| (PP) Month 3 (third week) N=10, 2 | 0.7 ± 0.1 | 0.9 ± 0.2 |
| (PP) Month 3 (fourth week) N=9, 0* | 0.8 ± 0.1 | NA ± NA |
| (PP) Month 5 N=11, 15 | 0.8 ± 0.2 | 0.7 ± 0.2 |
| (PP) Month 7 N=11, 14 | 0.8 ± 0.2 | 0.7 ± 0.2 |
| (PP) Month 9 N=11, 15 | 0.8 ± 0.2 | 0.8 ± 0.2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Everolimus | — | 7/19 (36.8%) | 19/19 (100%) |
| Reference Therapy | — | 7/17 (41.2%) | 15/17 (88.2%) |
| Event | Everolimus | Reference Therapy |
|---|---|---|
| Blood creatinine increasedInvestigations | 1/19 | 3/17 |
| Transplant rejectionImmune system disorders | 2/19 | 1/17 |
| DiarrhoeaGastrointestinal disorders | 0/19 | 1/17 |
| VomitingGastrointestinal disorders | 0/19 | 1/17 |
| PyrexiaGeneral disorders | 0/19 | 1/17 |
| Urinary tract infectionInfections and infestations | 1/19 | 1/17 |
| HypomagnesaemiaMetabolism and nutrition disorders | 0/19 | 1/17 |
| Abdominal painGastrointestinal disorders | 1/19 | 0/17 |
| Gastroenteritis viralInfections and infestations | 1/19 | 0/17 |
| Herpes zosterInfections and infestations | 1/19 | 0/17 |
| Event | Everolimus | Reference Therapy |
|---|---|---|
| HypomagnesaemiaMetabolism and nutrition disorders | 0/19 | 7/17 |
| ProteinuriaRenal and urinary disorders | 6/19 | 0/17 |
| LeukopeniaBlood and lymphatic system disorders | 5/19 | 1/17 |
| Aphthous stomatitisGastrointestinal disorders | 5/19 | 0/17 |
| Blood lactate dehydrogenaseInvestigations | 4/19 | 1/17 |
| Diabetes mellitusEndocrine disorders | 2/19 | 3/17 |
| Blood creatinine increasedInvestigations | 2/19 | 3/17 |
| DysuriaRenal and urinary disorders | 0/19 | 3/17 |
| AnaemiaBlood and lymphatic system disorders | 3/19 | 1/17 |
| Abdominal painGastrointestinal disorders | 3/19 | 0/17 |
Enrolled patient population included all patients who signed an informed consent regardless whether renal transplanation as performed or not.
| Age, Continuous(Years) | Everolimus | Reference Therapy | Total |
|---|---|---|---|
| Mean | 53.1 ± 13.4 | 49.6 ± 12.1 | 51.4 ± 12.7 |
| Sex: Female, Male(Participants) | Everolimus | Reference Therapy | Total |
|---|---|---|---|
| Female | 5 | 3 | 8 |
| Male | 14 | 14 | 28 |
The record gives a start of Dec 2009, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus